Biotech Values

[dewophile]

I think it would be worth a good amount if the phase 1 data are good. THRD had base data in phase 1 with greater heme toxicity etc. so normal phase 1 genuinely derisks the program
comparable early stage and even preclinnical companies have gotten in the ballpark of 200M for I/I assets along w billion(s) milestones and opt-ins or profit sharing
so yeah i guess do whatever research you want if you want on comps.